[26PO1-am2] Formulation testing-1/Dispensing, prescription audit and ordering/Drug information-1/Pharmacotherapies (Clinical)-1/(Basics)-1/Risk management/Others

[26PO1-am2-22] Assessing the bleeding risk in patients taking Dabigatran for catheter ablation by using eligibility criteria for large clinical trials of Dabigatran

○Yasuyuki Takashima^1,2, Minami Ohira³, Kosuke Doki^1,4, Masato Homma^1,4 (1. Dept. of Pharm. Sci., Graduate School of Comprehensive Human Sciences, Univ. of Tsukuba, 2. T-CReDO, 3. Aisei Pharmacy Co., Ltd., 4. Dept. of Pharm., Univ. of Tsukuba Hosp.)